Press coverage about Tabula Rasa HealthCare (NASDAQ:TRHC) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Tabula Rasa HealthCare earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.1912982957798 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Tabula Rasa HealthCare (TRHC) Upgraded by BidaskClub to Buy (americanbankingnews.com)
- Tabula Rasa HealthCare Subsidiary Partners with The Health Plan of San Mateo to deliver Comprehensive Medication Management Services (finance.yahoo.com)
- Should You Be Concerned About Tabula Rasa Healthcare Inc’s (NASDAQ:TRHC) -110.6% Earnings Decline? (finance.yahoo.com)
- Tabula Rasa HealthCare (TRHC) Now Covered by Analysts at Oppenheimer (americanbankingnews.com)
Several equities analysts have recently weighed in on TRHC shares. First Analysis began coverage on shares of Tabula Rasa HealthCare in a research report on Wednesday, November 1st. They set an “overweight” rating and a $41.00 price objective for the company. Piper Jaffray Companies reiterated an “overweight” rating and issued a $35.00 target price on shares of Tabula Rasa HealthCare in a report on Tuesday, November 7th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “strong-buy” rating and set a $31.00 target price for the company in a report on Wednesday, October 11th. Wells Fargo & Company raised their target price on shares of Tabula Rasa HealthCare from $21.00 to $27.00 and gave the stock a “market perform” rating in a report on Thursday, October 19th. Finally, William Blair began coverage on shares of Tabula Rasa HealthCare in a report on Monday, December 11th. They issued an “outperform” rating for the company. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Tabula Rasa HealthCare currently has an average rating of “Buy” and an average target price of $29.00.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $33.27 million during the quarter, compared to analyst estimates of $31.76 million. Tabula Rasa HealthCare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The firm’s revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.06 earnings per share. equities research analysts predict that Tabula Rasa HealthCare will post 0.05 EPS for the current fiscal year.
In related news, insider Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $26.68, for a total transaction of $213,440.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Orsula V. Knowlton sold 123,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $25.97, for a total transaction of $3,194,310.00. The disclosure for this sale can be found here. Insiders sold 1,099,180 shares of company stock valued at $28,435,203 over the last three months. 45.80% of the stock is owned by insiders.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
What are top analysts saying about Tabula Rasa HealthCare? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tabula Rasa HealthCare and related companies.